Stein, Rhona <br/><br/>
Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways.  [electronic resource] 

 -  Blood  Jun 2010 
 - 5180-90 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2009-06-228288  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--immunology<br/>Antigens, CD--immunology<br/>B-Lymphocytes<br/>Cell Line, Tumor<br/>Cytotoxins--immunology<br/>Drug Screening Assays, Antitumor<br/>Enzyme Activation--drug effects<br/>Extracellular Signal-Regulated MAP Kinases--immunology<br/>Female<br/>HLA-DR Antigens--immunology<br/>Hematologic Neoplasms--drug therapy<br/>Humans<br/>MAP Kinase Kinase 4--immunology<br/>MAP Kinase Signaling System--drug effects<br/>Mice<br/>Mice, SCID